Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 2,445

The DOI matches its Crossref record; 219 of the 219 references it cites were found in a registry or an index.

Rheumatoid arthritis

Open access
Smolen, Josef S., Aletaha, Daniel, Barton, Anne, Burmester, Gerd R., Emery, Paul, Firestein, Gary S., Kavanaugh, Arthur, McInnes, Iain B., Solomon, Daniel H., Strand, Vibeke, Yamamoto, Kazuhiko · 2018 · Nature Reviews Disease Primers

Abstract

Rheumatoid arthritis (RA) is a chronic, inflammatory, autoimmune disease that primarily affects the joints and is associated with autoantibodies that target various molecules including modified self-epitopes. The identification of novel autoantibodies has improved diagnostic accuracy, and newly developed classification criteria facilitate the recognition and study of the disease early in its course. New clinical assessment tools are able to better characterize disease activity states, which are correlated with progression of damage and disability, and permit improved follow-up. In addition, better understanding of the pathogenesis of RA through recognition of key cells and cytokines has led to the development of targeted disease-modifying antirheumatic drugs. Altogether, the improved understanding of the pathogenetic processes involved, rational use of established drugs and development of new drugs and reliable assessment tools have drastically altered the lives of individuals with RA over the past 2 decades. Current strategies strive for early referral, early diagnosis and early start of effective therapy aimed at remission or, at the least, low disease activity, with rapid adaptation of treatment if this target is not reached. This treat-to-target approach prevents progression of joint damage and optimizes physical functioning, work and social participation. In this Primer, we discuss the epidemiology, pathophysiology, diagnosis and management of RA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrdp.2018.1

Cites

219 of 219 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 201–219 of 219

Research works printed but not linked: 40

  1. Malemba, J. J. et al. The epidemiology of rheumatoid arthritis in Kinshasa, Democratic Republic of Congo—a population-based study. Rheumatology 51, 1644–1647 (2012). · doi:10.1093/rheumatology/kes092
  2. Naciute, M. et al. Frequency and significance of parvovirus B19 infection in patients with rheumatoid arthritis. J. Gen. Virol. 97, 3302–3312 (2016). · doi:10.1099/jgv.0.000621
  3. Aletaha, D., Alasti, F. & Smolen, J. S. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. Arthritis Res. Ther. 17, 229 (2015). · doi:10.1186/s13075-015-0736-9
  4. Bohler, C., Radner, H., Smolen, J. S. & Aletaha, D. Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. Ann. Rheum. Dis. 72, 241–244 (2013). · doi:10.1136/annrheumdis-2012-202297
  5. Castor, C. W. The microscopic structure of normal human synovial tissue. Arthritis Rheum. 3, 140–151 (1960). · doi:10.1002/art.1780030205
  6. Ziff, M. Relation of cellular infiltration of rheumatoid synovial membrane to its immune response. Arthritis Rheum. 17, 313–319 (1974). · doi:10.1002/art.1780170317
  7. Nakano, S. et al. Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. Rheumatology 54, 1498–1506 (2015). · doi:10.1093/rheumatology/keu528
  8. Theander, L. et al. Severe extraarticular manifestations in a community-based cohort of patients with rheumatoid arthritis: risk factors and incidence in relation to treatment with tumor necrosis factor inhibitors. J. Rheumatol 44, 981–987 (2017). · doi:10.3899/jrheum.161103
  9. Hazlewood, G. et al. Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e initiative. J. Rheumatol. Suppl. 87, 54–58 (2011). · doi:10.3899/jrheum.101076
  10. Gormley, G. J. et al. Can diagnostic triage by general practitioners or rheumatology nurses improve the positive predictive value of referrals to early arthritis clinics? Rheumatology 42, 763–768 (2003). · doi:10.1093/rheumatology/keg213
  11. van der Helm- van Mil, A. H. et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum. 56, 433–440 (2007). · doi:10.1002/art.22380
  12. McCarty, D. J. Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians. J. Rheumatol 17, 1117–1118 (1990).
  13. Haraoui, B. et al. Treating rheumatoid arthritis to target: a Canadian physician survey. J. Rheumatol. 39, 949–953 (2012). · doi:10.3899/jrheum.111134
  14. Solomon, D. H. et al. Implementation of treat to target in rheumatoid arthritis through a learning collaborative: results of the TRACTION trial. Arthritis Rheumatol. (in press).
  15. Van der Heijde, D. M.F. M., van't Hof, M., van Riel, P. L. & van de Putte, L. B. A. Development of a disease activity score based on judgement in clinical practice by rheumatologists. J. Rheumatol 20, 579–581 (1993).
  16. Bakker, M. F., Jacobs, J. W., Verstappen, S. M. & Bijlsma, J. W. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann. Rheum. Dis. 66 (Suppl. 3), iii56–iii60 (2007). · doi:10.1136/ard.2007.078360
  17. Smolen, J. S. & Aletaha, D. The assessment of disease activity in rheumatoid arthritis. Clin. Exp. Rheumatol. 28 (Suppl. 59), S18–S27 (2010).
  18. Schneider, C. K. Biosimilars in rheumatology: the wind of change. Ann. Rheum. Dis. 72, 315–318 (2013). · doi:10.1136/annrheumdis-2012-202941
  19. Nam, J. L. et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 76, 1113–1136 (2017). · DOI
  20. Kavanaugh, A. et al. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Ann. Rheum. Dis.https://doi.org/10.1136/annrheumdis-2017-211871 (2017). · doi:10.1136/annrheumdis-2017-211871
  21. Stamm, T. et al. Induction of sustained remission in ealry inflammatory arthritis with the combination of infliximab plus methotrexate, methotrexate alone or placebo: the DINORA trial [abstract]. Ann. Rheum. Dis. 76 (Suppl. 2), 560 (2017). · doi:10.1136/annrheumdis-2017-eular.3743
  22. Holloway, K. & van Dijk, L. The World Medicines Situation 2011, Rational Use of Medicines 3rd edn (World Health Organzization, Geneva, 2011).
  23. Molloy, E. S., Calabrese, C. M. & Calabrese, L. H. The risk of progressive multifocal leukoencephalopathy in the biologic era: prevention and management. Rheum. Dis. Clin. North Am. 43, 95–109 (2017). · doi:10.1016/j.rdc.2016.09.009
  24. West, E. & Jonsson, S. W. Health-related quality of life in rheumatoid arthritis in Northern Sweden: a comparison between patients with early RA, patients with medium-term disease and controls, using SF-36. Clin. Rheumatol 24, 117–122 (2005). · doi:10.1007/s10067-004-0976-6
  25. Murillo, Y. A., Almagro, R. M., Campos-Gonzales, I. D. & Cardiel, M. H. Health related quality of life in rheumatoid arthritis, osteoarthritis, diabetes mellitus, end stage renal disease and geriatric subjects. Rheumatol. Clin. 11, 68–72 (2017).
  26. Shokri, A., Mottaghi, P. & Qolipour, K. Quality of life and its predictors among Iranian patients with rheumatoid arthritis: a systematic review. J. Health Res. 6, e24636 (2015).
  27. Gerhold, K. et al. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT. Rheumatology 54, 1858–1866 (2015). · DOI
  28. Strand, V. & Singh, J. in Targeted Treatment of the Rheumatic Diseases 1st edn (ed. Weisman, M. ) (Elsevier, Philadelphia, PA, 2009).
  29. Strand, V. & Khanna, D. The impact of rheumatoid arthritis and treatment on patients’ lives. Clin. Exp. Rheumatol. 28 (Suppl. 59), S32–S40 (2010).
  30. Wolfe, F., Michaud, K. & Strand, V. Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J. Rheumatol. 32, 583–589 (2005).
  31. Pincus, T., Richardson, B., Strand, V. & Bergman, M. J. Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents. Clin. Exp. Rheumatol. 32 (Suppl. 85), 47–54 (2014).
  32. Franke, L. C., Ament, A. J., van de Laar, M. A., Boonen, A. & Severens, J. L. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin. Exp. Rheumatol. 27 (Suppl. 55), S118–S123 (2009).
  33. Lundkvist, J., Kastäng, F. & Kobelt, G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur. J. Health Econ. 8 (Suppl. 2), S49–S60 (2008). · doi:10.1007/s10198-007-0088-8
  34. Bansback, N. et al. Triple therapy versus biologic therapy for active rheumatoid arthritis: a cost-effectiveness analysis. Ann. Intern. Med. 167, 8–16 (2017). · doi:10.7326/m16-0713
  35. Her, M. & Kavanaugh, A. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis. Clin. Exp. Rheumatol 30 (Suppl. 73), S107–S111 (2012).
  36. Gartner, M. et al. Immediate access rheumatology clinic: efficiency and outcomes. Ann. Rheum. Dis. 71, 363–368 (2012). · doi:10.1136/annrheumdis-2011-200315
  37. Puchner, R. et al. Efficacy and outcome of Rapid Access Rheumatology Consultation: an office-based pilot cohort study. J. Rheumatol. 43, 1130–1135 (2016). · doi:10.3899/jrheum.151210
  38. Gerlag, D. M. et al. A single infusion of rituximab delays the onset of arthritis in subjects at high risk of developing RA [abstract]. Arthritis Rheumatol. 68 (Suppl 10), 3028 (2016).
  39. Braun, J. & Rau, R. An update on methotrexate. Curr. Opin. Rheumatol. 21, 216–223 (2009). · doi:10.1097/bor.0b013e328329c79d
  40. Keen, H. I., Conaghan, P. G. & Tett, S. E. Safety evaluation of leflunomide in rheumatoid arthritis. Expert Opin. Drug Saf. 12, 581–588 (2013). · doi:10.1517/14740338.2013.798299

Cited by

See all 2,445

Metadata

Authors
Smolen, J. S., Aletaha, D., Barton, A., Burmester, G. R., Emery, P., Firestein, G. S., Kavanaugh, A., McInnes, I. B., Solomon, D. H., Strand, V., & Yamamoto, K.
Venue
Nature Reviews Disease Primers
Published
2018-02-08
Volume
4
Issue
1
Pages
18001-18001
ISSN
2056-676X (ISSN-L)
OpenAlex
W4211054359
Cited by
2,445
References
219
FWCI
35.27
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.